AWMSG issues Final Appraisal Recommendation on sildenafil (Revatio®) for treatment of pulmonary arterial hypertension in children

Source: All Wales Medicines Strategy Group (AWMSG) Area: Evidence > Drug Specific Reviews In its Final Appraisal Recommendation, the All Wales Medicines Strategy Group (AWMSG) is of the opinion that sildenafil (Revatio®) 10mg/ml powder for oral suspension is appropriate for specialist only prescribing within NHS Wales as an option for the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. The group had made note of the FDA safety alert and had obtained further advice from the MHRA and clinical experts to inform its decision.
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news